

Results for announcement to the market		
AFT Pharmaceuticals Limited		
Reporting Period	6 months to September 30 2024	
Previous Reporting Period	6 months to September 30 2023	
Currency	NZ\$	
	Amount (000s)	Percentage change
Revenue from continuing operations	\$86,713	Up 4%
Total Revenue	\$86,713	Up 4%
Net profit/(loss) from continuing operations	\$1,803	Down 155%
Total net profit/(loss)	\$1,803	Down 155%
Interim/Final Dividend		
<b>Quoted Equity Securities:</b>		
Amount per Quoted Equity Security	\$0.01600000	
Imputed amount per Quoted Equity Security	No imputation	
Record Date	20/06/2024	
Dividend Payment Date	04/07/2024	
	Current period	Prior comparable period
Net tangible assets per Quoted Equity Security	\$0.26	\$0.23
A brief explanation of any of the figures above necessary to enable the figures to be understood	<p>Accompanying this announcement are the Group's unaudited consolidated financial statements for the six months ended 30 September 2024. These financial statements and the half year results commentary dated 21 November 2024 provide the balance of information requirements in accordance with NZX Listing Rules and Appendix 2.</p> <p>Pursuant to ASX listing rule 1.15.3 AFT Pharmaceuticals Limited confirms that it continues to comply with the rules of its home exchange (NZX Main Board).</p>	
Authority for this announcement		
Name of person authorised to make this announcement	Malcolm Tubby	
Contact person for this announcement	Malcolm Tubby, Chief Financial Officer, AFT Pharmaceuticals Ltd	
Contact phone number	+64 9 488 0232	
Contact email address	malcolm.tubby@aftpharm.com	
Date of release through MAP	21 November 2024	

Unaudited financial statements accompany this announcement.